JP7695192B2 - 介在ニューロンにおける遺伝子発現を選択的に調節するための人工発現構築物 - Google Patents

介在ニューロンにおける遺伝子発現を選択的に調節するための人工発現構築物 Download PDF

Info

Publication number
JP7695192B2
JP7695192B2 JP2021543981A JP2021543981A JP7695192B2 JP 7695192 B2 JP7695192 B2 JP 7695192B2 JP 2021543981 A JP2021543981 A JP 2021543981A JP 2021543981 A JP2021543981 A JP 2021543981A JP 7695192 B2 JP7695192 B2 JP 7695192B2
Authority
JP
Japan
Prior art keywords
seq
expression
expression construct
enhancer
aav
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021543981A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513339A (ja
JP2022513339A5 (enExample
Inventor
ティン，ジョナサン
リーバイ，ボアズ・ピー
ミッチ，ジョン・ケイ
レイン，エドワード・セバスチャン
カルム，フランク
Original Assignee
アレン インスティテュート
シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレン インスティテュート, シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート filed Critical アレン インスティテュート
Publication of JP2022513339A publication Critical patent/JP2022513339A/ja
Publication of JP2022513339A5 publication Critical patent/JP2022513339A5/ja
Priority to JP2024187194A priority Critical patent/JP7829658B2/ja
Application granted granted Critical
Publication of JP7695192B2 publication Critical patent/JP7695192B2/ja
Priority to JP2026032511A priority patent/JP2026094314A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/106—Primate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Neurosurgery (AREA)
  • Environmental Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021543981A 2018-10-08 2019-10-03 介在ニューロンにおける遺伝子発現を選択的に調節するための人工発現構築物 Active JP7695192B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024187194A JP7829658B2 (ja) 2018-10-08 2024-10-24 介在ニューロンにおける遺伝子発現を選択的に調節するための人工発現構築物
JP2026032511A JP2026094314A (ja) 2018-10-08 2026-03-02 介在ニューロンにおける遺伝子発現を選択的に調節するための人工発現構築物

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862742835P 2018-10-08 2018-10-08
US62/742,835 2018-10-08
US201862749012P 2018-10-22 2018-10-22
US62/749,012 2018-10-22
US201962810281P 2019-02-25 2019-02-25
US62/810,281 2019-02-25
PCT/US2019/054539 WO2020076614A1 (en) 2018-10-08 2019-10-03 Artificial expression constructs for selectively modulating gene expression in interneurons

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024187194A Division JP7829658B2 (ja) 2018-10-08 2024-10-24 介在ニューロンにおける遺伝子発現を選択的に調節するための人工発現構築物

Publications (3)

Publication Number Publication Date
JP2022513339A JP2022513339A (ja) 2022-02-07
JP2022513339A5 JP2022513339A5 (enExample) 2022-10-11
JP7695192B2 true JP7695192B2 (ja) 2025-06-18

Family

ID=70164665

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021543981A Active JP7695192B2 (ja) 2018-10-08 2019-10-03 介在ニューロンにおける遺伝子発現を選択的に調節するための人工発現構築物
JP2024187194A Active JP7829658B2 (ja) 2018-10-08 2024-10-24 介在ニューロンにおける遺伝子発現を選択的に調節するための人工発現構築物
JP2026032511A Pending JP2026094314A (ja) 2018-10-08 2026-03-02 介在ニューロンにおける遺伝子発現を選択的に調節するための人工発現構築物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024187194A Active JP7829658B2 (ja) 2018-10-08 2024-10-24 介在ニューロンにおける遺伝子発現を選択的に調節するための人工発現構築物
JP2026032511A Pending JP2026094314A (ja) 2018-10-08 2026-03-02 介在ニューロンにおける遺伝子発現を選択的に調節するための人工発現構築物

Country Status (6)

Country Link
US (2) US12467064B2 (enExample)
EP (1) EP3864150A4 (enExample)
JP (3) JP7695192B2 (enExample)
AU (2) AU2019358806B2 (enExample)
CA (1) CA3115652A1 (enExample)
WO (1) WO2020076614A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025023947A (ja) * 2018-10-08 2025-02-19 アレン インスティテュート 介在ニューロンにおける遺伝子発現を選択的に調節するための人工発現構築物

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3781174A4 (en) 2018-04-09 2022-01-26 Allen Institute RESCUE OF VOLTAGE CONTROLLED SODIUM CHANNEL FUNCTION IN INHIBITORY NEURONS
JP7721568B2 (ja) * 2020-04-21 2025-08-12 アレン インスティテュート 新皮質層５グルタミン酸作動性ニューロンにおいて遺伝子発現を選択的に調節する人工発現構築物
WO2021248085A2 (en) 2020-06-04 2021-12-09 Allen Institute Artificial expression constructs for selectively modulating gene expression in inhibitory neocortical neurons
US20230302158A1 (en) * 2020-08-14 2023-09-28 Allen Institute Artificial expression constructs for modulating gene expression in striatal neurons
GB202013940D0 (en) 2020-09-04 2020-10-21 Synpromics Ltd Regulatory nucleic acid sequences
WO2022169884A2 (en) * 2021-02-02 2022-08-11 Allen Institute Artificial expression constructs for modulating gene expression in gabaergic neurons and astrocytes
CN116286917A (zh) * 2021-12-14 2023-06-23 中国科学院深圳先进技术研究院 重组载体及其构建方法和应用
EP4536835A2 (en) * 2022-06-13 2025-04-16 Allen Institute Artificial expression constructs for modulating gene expression in non-neuronal central nervous system cells
US20250382637A1 (en) * 2022-06-21 2025-12-18 Regel Therapeutics, Inc. Genetic regulatory elements and uses thereof
CN119060958A (zh) * 2023-12-15 2024-12-03 中国科学院深圳先进技术研究院 一种携带钙离子报告基因的神经元及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180078658A1 (en) 2015-03-31 2018-03-22 New York University Compositions and method for reducing seizures

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2002A (en) 1841-03-12 Tor and planter for plowing
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US5252334A (en) 1989-09-08 1993-10-12 Cygnus Therapeutic Systems Solid matrix system for transdermal drug delivery
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5851832A (en) 1991-07-08 1998-12-22 Neurospheres, Ltd. In vitro growth and proliferation of multipotent neural stem cells and their progeny
US5766948A (en) 1993-01-06 1998-06-16 The Regents Of The University Of California Method for production of neuroblasts
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US6001654A (en) 1994-01-28 1999-12-14 California Institute Of Technology Methods for differentiating neural stem cells to neurons or smooth muscle cells using TGT-β super family growth factors
US5697899A (en) 1995-02-07 1997-12-16 Gensia Feedback controlled drug delivery system
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US6048964A (en) 1995-12-12 2000-04-11 Stryker Corporation Compositions and therapeutic methods using morphogenic proteins and stimulatory factors
US5656016A (en) 1996-03-18 1997-08-12 Abbott Laboratories Sonophoretic drug delivery system
US5753506A (en) 1996-05-23 1998-05-19 Cns Stem Cell Technology, Inc. Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals
US5797898A (en) 1996-07-02 1998-08-25 Massachusetts Institute Of Technology Microchip drug delivery devices
US5783208A (en) 1996-07-19 1998-07-21 Theratech, Inc. Transdermal drug delivery matrix for coadministering estradiol and another steroid
US5779708A (en) 1996-08-15 1998-07-14 Cyberdent, Inc. Intraosseous drug delivery device and method
US5968829A (en) 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
AU3642601A (en) * 1999-11-05 2001-05-30 Avigen, Inc. Ecdysone-inducible adeno-associated virus expression vectors
US6395546B1 (en) 2000-02-01 2002-05-28 Neurogeneration, Inc. Generation of dopaminergic neurons from human nervous system stem cells
AU2002250064B2 (en) 2001-02-13 2008-01-17 University Of Florida Research Foundation, Inc. A bi-directional dual promoter complex with enhanced promoter activity for transgene expression in eukaryotes
EP1430114B1 (en) 2001-09-14 2012-01-18 Stem Cell Therapeutics Inc. Prolactin induced increase in neural stem cell numbers and therapeutical use thereof
AU2003219933A1 (en) 2002-02-25 2003-09-09 Vanderbilt University Expression system for human brain-specific voltage-gated sodium channel, type 1
CA2693712C (en) 2007-07-14 2018-05-29 The University Of Iowa Research Foundation Methods and compositions for treating brain diseases
US20120308530A1 (en) 2011-06-03 2012-12-06 Beijing Allgens Medical Science & Technology Co., Ltd. Materials Composition and Methods to Control Neural Progenitor and Stem Cell Attachment, Proliferation and Guide Cell Differentiation
US20150044667A1 (en) 2012-03-20 2015-02-12 The Trustees Of The University Of Pennsylvania Human papillomavirus 16 (hpv16) - related epilepsy
US9579399B2 (en) 2012-08-27 2017-02-28 Friedrich Miescher Institute For Biomedical Research Retinal OFF circuit-specific promoter
DE102014207498A1 (de) 2014-04-17 2015-10-22 Universitätsklinikum Hamburg-Eppendorf Viraler Vektor für den zielgerichteten Gentransfer in Gehirn und Rückenmark
HUE049036T2 (hu) 2015-04-17 2020-09-28 P&X Medical Nv Összetételek és szerszámok glaukóma kezelésére
PL3298134T3 (pl) 2015-05-16 2023-09-18 Genzyme Corporation Edycja genów mutacji głęboko intronowych
AU2016366549B2 (en) 2015-12-11 2022-11-10 California Institute Of Technology Targeting peptides for directing adeno-associated viruses (AAVs)
CN117821509A (zh) * 2017-04-03 2024-04-05 编码治疗公司 组织选择性转基因表达
US11980671B2 (en) 2017-07-26 2024-05-14 Duke University Use of bacterial voltage gated ion channels for human therapies
EP3781174A4 (en) 2018-04-09 2022-01-26 Allen Institute RESCUE OF VOLTAGE CONTROLLED SODIUM CHANNEL FUNCTION IN INHIBITORY NEURONS
US12467064B2 (en) * 2018-10-08 2025-11-11 Allen Institute Artificial expression constructs for selectively modulating gene expression in interneurons

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180078658A1 (en) 2015-03-31 2018-03-22 New York University Compositions and method for reducing seizures

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Nature Neuroscience，2016年，vol.19 no.12，pp.1743-1749
The Journal of Neuroscience，2000年，vol.20 no.2，pp.709-721

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025023947A (ja) * 2018-10-08 2025-02-19 アレン インスティテュート 介在ニューロンにおける遺伝子発現を選択的に調節するための人工発現構築物
JP7829658B2 (ja) 2018-10-08 2026-03-13 アレン インスティテュート 介在ニューロンにおける遺伝子発現を選択的に調節するための人工発現構築物

Also Published As

Publication number Publication date
AU2025208516A1 (en) 2025-08-28
CA3115652A1 (en) 2020-04-16
JP7829658B2 (ja) 2026-03-13
JP2022513339A (ja) 2022-02-07
WO2020076614A1 (en) 2020-04-16
AU2019358806B2 (en) 2025-06-05
AU2019358806A1 (en) 2021-05-20
JP2026094314A (ja) 2026-06-09
EP3864150A1 (en) 2021-08-18
EP3864150A4 (en) 2022-08-24
JP2025023947A (ja) 2025-02-19
US20210348195A1 (en) 2021-11-11
US12467064B2 (en) 2025-11-11
US20250223612A1 (en) 2025-07-10

Similar Documents

Publication Publication Date Title
JP7829658B2 (ja) 介在ニューロンにおける遺伝子発現を選択的に調節するための人工発現構築物
JP7608348B2 (ja) 選択されたニューロン細胞集団における遺伝子発現を選択的に調節するための人工発現コンストラクト
JP7721568B2 (ja) 新皮質層５グルタミン酸作動性ニューロンにおいて遺伝子発現を選択的に調節する人工発現構築物
JP2026021417A (ja) 抑制性新皮質ニューロンにおいて遺伝子発現を選択的に調節する人工発現構築物
US20230117172A1 (en) Artificial expression constructs for selectively modulating gene expression in non-neuronal brain cells
US20250235550A1 (en) Artificial expression constructs for modulating gene expression in the cerebellum and a secondary cell type
WO2022212585A1 (en) Artificial expression constructs for modulating gene expression in claustrum neurons
US20240018543A1 (en) Artificial expression constructs for modulating gene expression in chandelier cells
CA3259293A1 (en) ARTIFICIAL EXPRESSION CONSTRUCTIONS TO MODULATE GENE EXPRESSION IN NON-NEURONAL CELLS OF THE CENTRAL NERVOUS SYSTEM
US20250041454A1 (en) Artificial expression constructs for modulating gene expression in neocortical layer 4 or layer 5 intratelencephalic neurons

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220930

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231003

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240325

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241024

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241025

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20241209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250401

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250520

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250606

R150 Certificate of patent or registration of utility model

Ref document number: 7695192

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150